NCT06375473View on ClinicalTrials.gov

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

Not yet recruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

April 19, 2027

Study Completion Date

April 19, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Irinotecan liposome II combination therapy regimen

Irinotecan liposome II combination therapy regimen

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06375473 - Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter